Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/eci.13412 http://scihub22266oqcxt.onion/10.1111/eci.13412 32954492!7537029!32954492     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Clin+Invest 2020 ; 50 (11): e13412 Nephropedia Template TP {{tp|p=32954492|t=2020. The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19 |pdf=|usr=}}{{32954492}} gab.com Text The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19 JO: Eur J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=32954492 #FOAvip BACKGROUND: COVID-19 is a public health emergency that is spreading worldwide and seriously affecting the global economy. Data on the effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 remain limited. METHODS: In this retrospective study, epidemiological, clinical, laboratory, treatment and outcomes data of hospitalized patients with severe COVID-19 in Zhongnan Hospital of Wuhan University from January 1 to 7 March 2020, were collected. Binary logistic regression model was used to analyse risk factors for disease progression from severe COVID-19 illness to critical illness. The effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 disease were evaluated. RESULTS: The results of the multivariate analysis from 175 patients with severe COVID-19 indicate that the use of methylprednisolone was a protective factor against disease progression from severe to critical illness(P < .001; OR: 0.054 95% CI: 0.017-0.173). Among patients with severe COVID-19 aged < 65 years, both the proportion of patients who progressed to critical illness (42.2% vs 90.0%, P = .000) and the mortality(6.7% vs 30.0%, P = .002) were lower for patients in methylprednisolone group, compared with those in the non-methylprednisolone group, whereas no statistical differences between the methylprednisolone group and the non-methylprednisolone group were found among patients with COVID-19 older than 65 years. Moreover, both the levels of CD4(+) T lymphocyte counts (646 vs 463/microL, P = .007) and IL-6 (241.9 vs 82.8 pg/mL, P = .025) were higher among patients with severe COVID-19 aged < 65 years, compared with those patients >/= 65 years old. CONCLUSION: Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness. Twit Text FOAVip The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19 ????Eur J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=32954492 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32954492 #FOAvip English Wikipedia <ref>{{Cite pmid|32954492}}</ref> The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19 #MMPMID32954492 Yang R; Xiong Y; Ke H; Chen T; Gao S Eur J Clin Invest 2020[Nov]; 50 (11): e13412 PMID32954492show ga BACKGROUND: COVID-19 is a public health emergency that is spreading worldwide and seriously affecting the global economy. Data on the effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 remain limited. METHODS: In this retrospective study, epidemiological, clinical, laboratory, treatment and outcomes data of hospitalized patients with severe COVID-19 in Zhongnan Hospital of Wuhan University from January 1 to 7 March 2020, were collected. Binary logistic regression model was used to analyse risk factors for disease progression from severe COVID-19 illness to critical illness. The effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 disease were evaluated. RESULTS: The results of the multivariate analysis from 175 patients with severe COVID-19 indicate that the use of methylprednisolone was a protective factor against disease progression from severe to critical illness(P < .001; OR: 0.054 95% CI: 0.017-0.173). Among patients with severe COVID-19 aged < 65 years, both the proportion of patients who progressed to critical illness (42.2% vs 90.0%, P = .000) and the mortality(6.7% vs 30.0%, P = .002) were lower for patients in methylprednisolone group, compared with those in the non-methylprednisolone group, whereas no statistical differences between the methylprednisolone group and the non-methylprednisolone group were found among patients with COVID-19 older than 65 years. Moreover, both the levels of CD4(+) T lymphocyte counts (646 vs 463/microL, P = .007) and IL-6 (241.9 vs 82.8 pg/mL, P = .025) were higher among patients with severe COVID-19 aged < 65 years, compared with those patients >/= 65 years old. CONCLUSION: Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness. |*Hospital Mortality[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Analysis of Variance[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Chi-Square Distribution[MESH] |China/epidemiology[MESH] |Clinical Laboratory Techniques[MESH] |Coronavirus Infections/diagnosis/*drug therapy/epidemiology/*prevention & control[MESH] |Critical Illness/mortality[MESH] |DNA, Viral/*analysis[MESH] |Databases, Factual[MESH] |Disease Progression[MESH] |Female[MESH] |Hospitalization/statistics & numerical data[MESH] |Hospitals, University[MESH] |Humans[MESH] |Male[MESH] |Methylprednisolone/*therapeutic use[MESH] |Middle Aged[MESH] |Pandemics/*prevention & control/statistics & numerical data[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/*prevention & control[MESH] |Polymerase Chain Reaction/methods[MESH] |Retrospective Studies[MESH] |Risk Assessment[MESH]The role of methylprednisolone on preventing disease progression for h(epmc).pdf DeepDyve Pubget Overpricing